TEAR: TearLab Corporation Market Currents

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 12:45 PM Midday top 10 gainers: PDII +31%. UNTK +22%. ALIM +19%. SODA +15%. CHLN +15%. TEAR +14%. ESI +14%. ECTY +14%. BVSN +12%. RVLT 12%.
Midday top 10 losers: TELOZ -28%. OPXA -19%. SED -16%. STXS -14%. FMAR -13%. VELT -12%. TSRE -12%. TRMD -11%. CCCL -10%. PT -10%. Comment! [On the Move]
Tuesday, May 14, 10:23 AM TearLab (TEAR +10.6%) ramps higher this morning after reporting Q1 sales that topped the Street's $2.19M estimate. Net revenues soared 486% from the same period last year, and an increase of 54% sequentially from the previous quarter. A total of 388 orders for its TearLab Osmolarity systems were booked in Q1. Net losses for the quarter were $9.1M, including approximately $6.6M in non-cash expense related to the revaluation of warrants issued in June 2011. As of March 31, the company had $12.3M remaining in cash. Comment! [Healthcare, Earnings, On the Move]
Monday, May 13, 4:33 PM TearLab (TEAR): Q1 EPS of -$0.30 misses by $0.18. Revenue of $2.48M beats by $0.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 10:24 AM TearLab (TEAR -2%) "will clearly need to issue a sizable amount of equity at a price of $6 or below," writes SA contributor Richard Pearson who goes on to call the company "a serial dilution machine" and questions the size of the market for the TEAR's products. Pearson's commentary refutes bullish analysis from what he calls "small, retail-oriented brokerages." TEAR's shares are up ~160% since last June and the company beat on the top line each of the last two quarters (I, II). Comment! [Healthcare]
Wednesday, March 20, 7:36 AM TearLab (TEAR): Q4 EPS of -$0.13 misses by $0.03. Revenue of $1.61M beats by $0.02M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, November 13, 2012, 7:38 AM TearLab (TEAR): Q3 EPS of -$0.17 misses by $0.06. Revenue of $1.21M (+264% Y/Y) beats by $0.2M. (PR) Comment! [Earnings, Healthcare]
Wednesday, August 29, 2012, 9:16 AM TearLab (TEAR) +6.2% premarket after Canaccord Genuity initiates coverage with a Buy rating a $6 price target, noting the company offers the first point of care instrument that can quantitatively measure and diagnose dry eye disease. The firm says U.S. market potential includes 50,000 eye specialists who see on average six dry eye patients per day, equaling a $1.8B opportunity. Comment! [Healthcare, Quick Ideas, On the Move]
Wednesday, August 29, 2012, 9:10 AM Premarket gainers: JOSB +14%. TEAR +8%. MCP +6%. TFM +5%.
Losers: ARQL -26%. WCRX -22%. DY -17%. JASO -9%. FRO -8%. Comment! [On the Move]
Tuesday, April 10, 2012, 7:10 PM TearLab (TEAR) trades lower in the post-session after announcing a secondary offering to sell an undisclosed number of shares of common stock. Proceeds from the offering will be used for working capital and general corporate purposes. Shares -5% AH. Comment! [Tech]

TEAR TearLab Corporation

TEAR

TearLab Corporation